Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Regional Hospital Holstebro
ClinicalTrials.gov Identifier:
NCT00344955
First received: June 24, 2006
Last updated: May 14, 2008
Last verified: May 2008

June 24, 2006
May 14, 2008
January 2003
December 2003   (final data collection date for primary outcome measure)
  • GFR
  • RPF
  • FEna
  • FELi
  • CLna
  • CLli
Same as current
Complete list of historical versions of study NCT00344955 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects
Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

We wanted to test the acute effect of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Healthy
Drug: HMG-CoA reductase inhibition (atorvastatin)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
December 2003
December 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Both men and women
  • Age: Between 20-50
  • BMI<30

Exclusion Criteria:

  • Clinical signs or history of disease of heart, lungs, kidneys or endocrine organs.
  • Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose)
  • Albuminuria or glucosuria
  • Cancer
  • Art. hypertension
  • Alcohol abuse
  • Medical treatment, except oral contraceptives
  • Pregnancy or breast feeding
  • Blood donation less than 1 month before study
Both
20 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00344955
MED.RES.HOS.2004.01.LP
Not Provided
Not Provided
Regional Hospital Holstebro
Not Provided
Study Chair: Erling B. Pedersen, Professor Holstebro Sygehus
Regional Hospital Holstebro
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP